

CITATION REPORT

List of articles citing

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

DOI: 10.7326/0003-4819-130-6-199903160-00005
Annals of Internal Medicine, 1999, 130, 487-95.

Source: <https://exaly.com/paper-pdf/31072996/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
500	Leukotriene receptor antagonist drugs for asthma. 1999 , 171, 378-81		2
499	Inhaled beclomethasone versus placebo for chronic asthma. 2000 , CD002738		20
498	The problems of treating adolescent asthma: what are the alternatives to inhaled therapy?. 1999 , 93, 677-84		14
497	Anti-leucotriènes (3) : leur place dans le traitement de l'asthme. 1999 , 39, 546-550		
496	Genetic and environmental interaction in allergy and asthma. 1999 , 104, 1139-46		141
495	Montelukast: data from clinical trials in the management of asthma. 1999 , 33, 1299-314		25
494	Use of leukotriene antagonists in childhood asthma. 1999 , 11, 540-7		12
493	New millennium bronchodilators for asthma: single-isomer beta agonists. 2000 , 6, 43-9		25
492	Prevention of asthma morbidity: recent advances. 2000 , 12, 438-43		2
491	Effects of depressive symptoms on health-related quality of life in asthma patients. 2000 , 15, 301-10		133
490	Unmet needs in adult asthma. 2000 , 30 Suppl 1, 66-9		4
489	Update in internal medicine. 2000 , 31, 329-52		
488	montelukast, astmaMontelukast bij astma, montelukastastma, beclometasonastma?. 2000 , 38, 156-157		
487	Outcome measures in asthma. 2000 , 55 Suppl 1, S70-4		4
486	Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. 2000 , 55, 478-83		43
485	A severe systemic inflammatory reaction following therapy with montelukast (Singulair). 2000 , 15, 1054-5		4
484	Effects of antileukotrienes in the treatment of asthma. 2000 , 161, S73-6		31

483	Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. 2000 , 161, 1881-6	141
482	Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. 2000 , 162, 187-90	96
481	Why does airway inflammation persist? Is it leukotrienes?. 2000 , 161, S186-7	21
480	Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). 2000 , 94, 612-21	40
479	[Role of leukotriene inhibitors in the treatment of childhood asthma]. 2000 , 7, 969-75	2
478	Clinical evidence with montelukast in the management of chronic childhood asthma. 2000 , 59 Suppl 1, 29-34; discussion 43-5	12
477	Tolerability of montelukast. 2000 , 59 Suppl 1, 35-42; discussion 43-5	21
476	Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. 2000 , 85, 398-406	37
475	Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections. 2000 , 106, S171-8	21
474	Letters to the editor. 2000 , 84, 638-639	1
473	Antileukotriene agents and aspirin-sensitive asthma: are we removing the second bassoonist or skating to where the puck is gonna be?. 2000 , 85, 5-8	4
472	Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. 2000 , 105, 1123-9	111
471	Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. 2000 , 106, 1088-95	182
470	Drug-induced respiratory disorders: incidence, prevention and management. 2000 , 23, 143-64	34
469	Montelukast: a review of its therapeutic potential in persistent asthma. 2000 , 59, 891-928	70
468	Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. 2000 , 60, 1141-78	53
467	Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. 2001 , 107, 398-416	53
466	Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. 2001 , 107, 461-8	135

465	Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. 2001 , 24, 1065-80	33
464	Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?. 2001 , 61, 391-418	13
463	Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. 2001 , 61, 1325-50	44
462	Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. 2001 , 41, 612-9	35
461	A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. 2001 , 111, 195-202	19
460	Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. 2001 , 95, 227-34	66
459	Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. 2001 , 95, 379-86	30
458	History and future perspectives of treating asthma as a systemic and small airways disease. 2001 , 95, 703-19	82
457	Regulation of leukotrienes in the management of asthma: biology and clinical therapy. 2001 , 52, 1-14	57
456	Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy. 2001 , 23, 701-14	6
455	Comparing discriminative validity between a disease-specific and a general health scale in patients with moderate asthma. 2001 , 54, 263-74	30
454	Use of Montelukast in tapering inhaled corticosteroid therapy: an open-label, 48-week trial. 2001 , 62, 743-755	6
453	Efficacy of antileukotriene agents in asthma management. 2001 , 86, 9-17	29
452	The role of antileukotrienes in the treatment of asthma. 2001 , 86, 31-9	30
451	STATUS ASTHMATICUS AND HOSPITAL MANAGEMENT OF ASTHMA. 2001 , 21, 503-533	
450	Comparative efficacy of inhaled corticosteroids and antileukotriene drugs in asthma. 2001 , 15, 239-49	15
449	Consensus guidelines for asthma therapy. 2001 , 86, 40-4	17
448	Asthma treatment with inhaled corticosteroids versus antileukotrienes: what exhaled nitric oxide studies do and do not tell us. 2001 , 87, 257-60	3

447	Montelukast: oral alternative to inhaled therapy for persistent asthma. 2001 , 17, 1-6	4
446	What are the alternatives to increasing inhaled corticosteroids for the long term control of asthma?. 2001 , 15, 185-98	3
445	Self-efficacy, depressive symptoms, and patients' expectations predict outcomes in asthma. 2001 , 39, 1326-38	118
444	New combination therapies for asthma. 2001 , 7, 62-8	16
443	The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. 2001 , 119, 1533-46	97
442	Correlation of airway obstruction and patient-reported endpoints in clinical studies. 2001 , 17, 220-4	62
441	Is overall asthma control being achieved? A hypothesis-generating study. 2001 , 17, 589-95	72
440	The pharmacogenetics of asthma: a candidate gene approach. 2001 , 1, 27-37	21
439	Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. 2001 , CD003133	10
438	Use of oral montelukast in the treatment of asthma. 2001 , 27, 148-55	4
437	Expedient liquid chromatographic method with fluorescence detection for montelukast sodium in micro-samples of plasma. 2001 , 754, 527-31	29
436	Effect of a specific cysteinyl leukotriene-receptor 1-antagonist (montelukast) on the transmigration of eosinophils across human umbilical vein endothelial cells. 2001 , 31, 836-44	27
435	Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. 2001 , 31, 845-54	58
434	Does leukotriene modulation of eosinophil function explain the therapeutic effectiveness of receptor antagonists in some patients with asthma?. 2001 , 31, 806-7	2
433	An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. 2001 , 31, 1385-91	95
432	Outcome measures in asthma. 2001 , 1, 261-263	1
431	New therapeutic indications for Cys-LT1 antagonists: atopic dermatitis and urticaria. 2001 , 1, 156-159	2
430	Emerging understanding of the role of LTRAs in disease modification and anti-inflammatory effect. 2001 , 1, 34-38	

429	Determinants of clinical responses in asthma. 2001 , 1, 229-234	2
428	Clinical efficacy of montelukast in adults and children. 2001 , 1, 264-273	11
427	CysLT1 antagonists in the treatment of atopic dermatitis and urticaria. 2001 , 1, 305-308	1
426	Issues and challenges in pediatric asthma. 2001 , 56 Suppl 66, 18-21	3
425	The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood. 2001 , 56 Suppl 66, 22-9	22
424	Pediatric asthma: "Real world" measures of effectiveness. 2001 , 21, 31-7	5
423	Pharmacogenetic applications of the Human Genome project. 2001 , 7, 281-3	76
422	Leukotriene receptor antagonists in the treatment of asthma. 2001 , 21, 34S-37S	9
421	Clinical considerations in the use of inhaled corticosteroids for asthma. 2001 , 21, 38S-48S	10
420	Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone. 2001 , 164, 759-63	58
419	Management Considerations for Chronic Asthma. 2001 , 14, 108-125	
418	Leukotriene modifiers in pediatric asthma management. 2001 , 107, 381-90	77
417	Clinical practice. Mild asthma. 2001 , 345, 1257-62	17
416	Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. 2002 , 165, 9-14	253
415	Successful US paediatric public health campaigns. 2002 , 87, 290	1
414	Efficacy and Safety of Low-Dose Fluticasone Propionate Compared With Montelukast for Maintenance Treatment of Persistent Asthma. 2002 , 77, 437-445	25
413	Pharmacogenetics of treatment with leukotriene modifiers. 2002 , 2, 395-401	8
412	Where do leukotriene modifiers fit in asthma management?. 2002 , 27, 19, 23-4, 26-9; quiz 30-1	3

411	Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma. 2000 , CD002314	19
410	Marginal utility of montelukast for persistent asthma. 2002 , 121, 334-7	7
409	Arachidonic Acid-Derived Bioactive Lipids: Their Role and the Role for Their Inhibitors in Dermatology. 2002 , 6, 241-256	5
408	Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. 2002 , 113, 15-21	20
407	Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. 2002 , 109, 68-74	55
406	Significant variability in response to inhaled corticosteroids for persistent asthma. 2002 , 109, 410-8	500
405	Airway inflammation in asthma and its consequences: implications for treatment in children and adults. 2002 , 109, S539-48	36
404	The natural history of asthma and early intervention. 2002 , 109, S549-53	15
403	The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. 2002 , 110, 96-101	102
402	The risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonist. 2002 , 110, 39-41	19
401	Effects of montelukast and beclomethasone on airway function and asthma control. 2002 , 110, 847-54	95
400	New frontiers in acute asthma therapy. 2002 , 3, 173-180	
399	Targeting cysteinyl leukotrienes in patients with rhinitis, sinusitis and paranasal polyps. 2002 , 1, 403-8	9
398	The role of leukotriene inhibitors in allergic rhinitis and paranasal sinusitis. 2002 , 3, 33-8	3
397	Antileukotrienes complement corticosteroids in management of mild to moderate persistent asthma. 2002 , 18, 6-8	
396	Comparison of oral montelukast and inhaled fluticasone in the treatment of asthma associated with chronic rhinopolyposis: a single-blind, randomized, pilot study. 2002 , 63, 355-365	6
395	A novel approach to defining the relationship between lung function and symptom status in asthma. 2002 , 55, 11-8	16
394	The management of acute severe asthma. 2002 , 23, 257-68	18

393	Leukotriene modifiers. 2002 , 86, 1009-33, vi	13
392	[Reflections on antileukotrienes]. 2002 , 29, 356-8	
391	Efficacy and Safety of Low-Dose Fluticasone Propionate Compared With Montelukast for Maintenance Treatment of Persistent Asthma. 2002 , 77, 437-445	36
390	The pharmacogenetics of asthma and allergic disease. 2002 , 22, 223-241	1
389	Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. 2002 , 88, 227-35	49
388	The use of inhaled corticosteroids in adult asthma. 2002 , 86, 1035-47	4
387	Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. 2002 , 88, 401-9	40
386	Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. 2002 , 88, 23-9	33
385	The role of antileukotrienes in the treatment of asthma. 2002 , 15, 171-182	9
384	Management of Chronic Asthma in Adults. 2002 , 675-687	
383	Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis. 2002 , 22, 1117-23	9
382	Pharmacoeconomic studies of asthma controller drugs: marketing gimmick or icing on the cake?. 2002 , 22, 131-3	2
381	Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. 2002 , 22, 166-74	23
380	Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management. 2002 , 22, 212-26	16
379	Quality assurance of asthma clinical trials. 2002 , 23, 143-56	21
378	The role of leukotriene inhibitors in allergic rhinitis and paranasal sinusitis. 2002 , 2, 239-44	15
377	Treatment of asthmatic patients with a cysteinyl leukotriene receptor-1 antagonist montelukast (Singulair), decreases the eosinophil survival-enhancing activity produced by peripheral blood mononuclear leukocytes in vitro. 2002 , 57, 1021-8	10
376	Leukotriene receptor antagonists in the treatment of asthma: an update. 2002 , 57 Suppl 72, 16-9	25

375	Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. 2002 , 32, 1180-6	27
374	Safety of inhaled corticosteroids in children. 2002 , 33, 208-20	80
373	A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. 2003 , 55, 609-15	12
372	Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. 2003 , 33, 1380-8	87
371	Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC ₄ synthase A(-444)C polymorphism. 2003 , 36, 413-20	34
370	Reply. 2003 , 111, 1413-1414	
369	Leukotriene receptor antagonists in asthma therapy. 2003 , 111, S62-70	13
368	The pharmacologic management of childhood asthma. 2003 , 50, 609-29	7
367	Study design is a major determinant of whether equivalence or superiority is demonstrated. 2003 , 111, 1413; author reply 1413-4	1
366	Benefit-risk assessment of antileukotrienes in the management of asthma. 2003 , 26, 483-518	34
365	Pranlukast: a review of its use in the management of asthma. 2003 , 63, 991-1019	46
364	Response to montelukast among subgroups of children aged 2 to 14 years with asthma. 2003 , 111, 757-62	34
363	Heterogeneity in the pathology and treatment of asthma. 2003 , 115 Suppl 3A, 49S-54S	37
362	Re: Symptomatic asthma: attendance and prescribing in general practice (Respir Med 96: 102-109): Critique of Nolan and White. 2003 , 97, 290	1
361	The role of leukotrienes in asthma. 2003 , 69, 145-55	61
360	Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild-moderate persistent asthma. 2003 , 16, 111-4	20
359	Pharmacology of airway inflammation in asthma and COPD. 2003 , 16, 247-77	83
358	Effect of montelukast on polymorphonuclear leukocyte functions in asthmatic patients. 2003 , 3, 1257-60	3

357	The assessment of childhood asthma. 2003 , 50, 593-608	2
356	Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. 2003 , 91, 309-13	35
355	Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. 2003 , 111, S18-34; discussion S34-6	236
354	Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists. 2003 , 63 Suppl 2, 1-20	18
353	Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting beta2-agonists on asthma pathophysiology: a review of the evidence. 2003 , 63 Suppl 2, 35-51	16
352	Treatment of childhood asthma: how do the available options compare?. 2003 , 5, 685-98	1
351	Inhaled corticosteroids for asthma: common clinical quandaries. 2003 , 40, 107-18	12
350	Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. 2003 , 58, 211-6	139
349	Efficacy of montelukast in the treatment of chronic obstructive pulmonary disease in five horses. 2003 , 152, 804-6	13
348	Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. 2003 , 326, 621	62
347	Asthma and the human genome project: summary of the 45th Annual Thomas L. Petty Aspen Lung Conference. 2003 , 123, 447S-9S	10
346	The role of leukotriene inhibitors in patients with paranasal sinus disease. 2003 , 11, 184-91	28
345	Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. 2003 , 43, 342-58	89
344	Is forced expiratory volume in one second the best measure of severity in childhood asthma?. 2004 , 169, 784-6	91
343	Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. 2004 , 13, 1353-9	267
342	Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. 2004 , CD002314	42
341	TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. 2004 , 101, 18099-104	144
340	The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. 2004 , 20, 1549-58	139

339	Dietary intake of soy genistein is associated with lung function in patients with asthma. 2004 , 41, 833-43	44
338	The reuse of subjects in clinical studies: is a bias introduced? Is there a threat to study validity?. 2004 , 41, 305-9	3
337	An Endpoint for Worsening Asthma: Development of a Sensitive Measure and its Properties. 2004 , 38, 5-13	1
336	Comparative effect of triamcinolone, nedocromil and montelukast on asthma control in children: A randomized pragmatic study. 2004 , 15, 359-64	7
335	Comparison of glucocorticoid and cysteinyl leukotriene receptor antagonist treatments in an experimental model of chronic airway inflammation in guinea-pigs. 2004 , 34, 145-52	34
334	Effect of montelukast compared with inhaled fluticasone on airway inflammation. 2004 , 34, 1388-94	19
333	Asthma treatment in the 21st century: what's next?. 2004 , 27, 197-205	3
332	An update of the leukotriene modulators for the treatment of asthma. 2004 , 13, 763-76	7
331	Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline. 2004 , 93, 373-80	9
330	The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes. 2004 , 93, 538-45	42
329	Mediator Antagonists and Anti-Allergic Drugs. 2004 , 125-150	
328	Inhaled corticosteroids versus leukotriene antagonists as first-line therapy for asthma: a systematic review of current evidence. 2004 , 3, 399-405	10
327	Current and emerging nonsteroidal anti-inflammatory therapies targeting specific mechanisms in asthma and allergy. 2004 , 3, 235-46	18
326	The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma. 2004 , 26, 1895-904	16
325	Therapeutic responses in asthma and COPD. Corticosteroids. 2004 , 126, 138S-149S; discussion 159S-161S	28
324	Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. 2004 , CD003133	27
323	Roundtable Discussion. 2004 , 126, 159S-161S	14
322	Asthma and Health-Related Quality of Life. 2005 , 54, 61-70	1

321	The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. 2005 , 127, 509-14	60
320	Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. 2005 , CD003137	38
319	Inhaled beclomethasone versus placebo for chronic asthma. 2005 , CD002738	65
318	Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. 2006 , 61, 72-8	83
317	ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. 2006 , 61, 97-103	54
316	Effects of montelukast on symptoms and eNO in children with mild to moderate asthma. 2005 , 47, 622-6	7
315	Pharmacy-specific quality indicators for asthma therapy. 2005 , 1, 430-45	5
314	Asthma-related health care resource use among patients starting fluticasone or montelukast therapy. 2005 , 25, 1752-60	9
313	Pharmacogenetic approaches in the treatment of asthma. 2005 , 5, 101-8	37
312	Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis. 2005 , 60, 902-8	18
311	How pharmacogenomics will play a role in the management of asthma. 2005 , 172, 12-8	35
310	Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. 2005 , 60, 100-5	32
309	Cysteinyl Leukotrienes in Allergic Inflammation. 2005 , 127, 1312-1326	2
308	Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. 2005 , 365, 167-75	338
307	Gene-environment interactions in asthma and allergies: a new paradigm to understand disease causation. 2005 , 25, 709-21	38
306	The challenge of mild persistent asthma. 2005 , 94, 517-27; quiz 527-9, 574	5
305	Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. 2005 , 116, 360-9	143
304	Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. 2005 , 147, 213-20	79

303	Controlling asthma: the role of nutrition. 2005 , 1, 393-5	6
302	The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma. 2005 , 18, 374-80	27
301	Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. 2005 , 115, 233-42	458
300	Overcoming gaps in the management of asthma in older patients: new insights. 2005 , 22, 1029-59	34
299	Corticosteroid insensitivity in smokers with asthma : clinical evidence, mechanisms, and management. 2006 , 5, 467-81	17
298	Pharmacogenomics and the future of drug therapy. 2006 , 53, 591-619	15
297	Cost effectiveness of leukotriene modifiers in adults with asthma. 2006 , 24, 727-42	5
296	Wheezing in Older Children: Asthma. 2006 , 810-838	2
295	The expanding role of leukotriene receptor antagonists in chronic asthma. 2006 , 97, 731-41, quiz 741-2, 793	21
294	Effect of montelukast on peripheral airflow obstruction in children with asthma. 2006 , 96, 541-9	33
293	Facteurs prédictifs de la réponse et de la tolérance au traitement de l'asthme. 2006 , 23, 49-54	
292	Pharmacogenetics of asthma: where are we now?. 2006 , 27, 109-17, vii	0
291	Acute asthma exacerbations: phenotypes and management. 2006 , 27, 99-108, vi-vii	13
290	Genetics of allergic disease. 2006 , 90, 1-15	11
289	Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. 2006 , 96, 800-7	60
288	Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. 2006 , 117, 45-52	204
287	Pharmacogénomique de l'asthme. 2006 , 46, 552-555	
286	Bronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a beta2-agonist. 2006 , 19, 272-80	20

285	Comparative improvement of asthma symptoms and expiratory flows after corticosteroid treatment: a method to assess the effect of corticosteroids on large vs. small airways?. 2006 , 100, 496-502	3
284	Childhood asthma: breakthroughs and challenges. 2006 , 53, 55-100	4
283	Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. 2006 , CD003137	65
282	Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. 2006 , 130, 1726-32	53
281	Developing a research strategy for acupuncture. 2006 , 22, 632-8	38
280	927T>C polymorphism of the cysteinyl-leukotriene type-1 receptor (CYSLTR1) gene in children with asthma and atopic dermatitis. 2006 , 17, 323-8	26
279	The cysteinyl-leukotriene type 1 receptor polymorphism 927T/C is associated with atopy severity but not with asthma. 2006 , 36, 735-41	31
278	Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. 2006 , 36, 1494-504	73
277	Overview of the pharmacogenetics of asthma treatment. 2006 , 6, 311-26	72
276	Treatment of asthma with antileukotrienes: first line or last resort therapy?. 2006 , 533, 40-56	83
275	A framework to evaluate the economic impact of pharmacogenomics. 2006 , 7, 853-62	25
274	Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. 2006 , 173, 379-85	193
273	Cysteinyl leukotriene levels in esophageal mucosal biopsies of children with eosinophilic inflammation: are they all the same?. 2006 , 101, 1125-8	53
272	Once-Daily Mometasone Furoate Administered by Dry Powder Inhaler for the Treatment of Children with Persistent Asthma. 2007 , 20, 67-82	8
271	Case records of the Massachusetts General Hospital. Case 15-2007. A 20-year-old woman with asthma and cardiorespiratory arrest. 2007 , 356, 2083-91	5
270	Clinical Decisions. Treatment of mild persistent asthma. 2007 , 356, 2096-100	9
269	Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. 2007 , 175, 228-34	65
268	Spoilt for choice?. 2007 , 175, 208-9	

267	Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. 2007 , 175, 783-90	319
266	Heterogeneity in response to asthma medications. 2007 , 7, 185-9	6
265	Asthma: new developments concerning immune mechanisms, diagnosis and treatment. 2007 , 13, 37-43	15
264	Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. 2007 , 17, 189-96	94
263	Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. 2007 , 101, 1183-90	10
262	Treatment strategies for reducing asthma-related emergency department visits. 2007 , 32, 27-39	6
261	Pharmacogenetics of the beta 2-adrenergic receptor gene. 2007 , 27, 665-84; vii	19
260	Facing the challenge of unmet needs in asthma. 2007 , 98, S16-S22	1
259	Targeted interventions for difficult-to-treat asthma. 2007 , 11, 11-20	1
258	Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. 2007 , 11, 97-104	45
257	Tolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review. 2007 , 44, 411-22	3
256	The management of adults and children with moderate severity asthma. 2007 , 49, 28-32	2
255	Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. 2007 , 175, 235-42	104
254	A cost-effectiveness analysis of first-line controller therapies for persistent asthma. 2007 , 25, 577-90	22
253	The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. 2007 , 119, 73-80	144
252	Achieving and maintaining asthma control in an urban pediatric disease management program: the Breathmobile Program. 2007 , 119, 1445-53	43
251	Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. 2007 , 119, 1454-61	202
250	Leukotrienes. 2007 , 357, 1841-54	830

249	Complexation study of cinalukast and montelukast with cyclodextrines. 2007 , 43, 1025-32	13
248	The pharmacogenetics research network: from SNP discovery to clinical drug response. 2007 , 81, 328-45	197
247	Effects of Rho-kinase inactivation on eosinophilia and hyper-reactivity in murine airways by allergen challenges. 2007 , 37, 599-607	47
246	Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. 2008 , 56, 7-11	4
245	Pharmacogenetics of asthma. 2008 , 448, 359-78	8
244	Asthma genetics: personalizing medicine. 2008 , 45, 257-64	16
243	Achieving asthma control in practice: understanding the reasons for poor control. 2008 , 102, 1681-93	169
242	Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down". 2008 , 45, 681-7	35
241	CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia. 2008 , 26, 3031-7	42
240	Age-related changes in eosinophil function in human subjects. 2008 , 133, 412-9	116
239	The Effects of Inhaled Fluticasone and Pranlukast on Bronchial Hyperreactivity in Children with Asthma. 2008 , 21, 173-178	
238	Genetic influences on response to asthma pharmacotherapy. 2008 , 1, 649-60	3
237	Leukotriene Modifiers. 2008 , 263-271	1
236	Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist. 2009 , 5, 923-33	9
235	Management of Chronic Asthma. 2009 , 761-774	1
234	Montelukast as an alternative to low-dose inhaled corticosteroids in the management of mild asthma (the SIMPLE trial): an open-label effectiveness trial. 2009 , 16 Suppl A, 11A-21A	16
233	Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). 2009 , 16 Suppl A, 17A-31A	29
232	Montelukast as add-on therapy to inhaled corticosteroids in the management of asthma (the SAS trial). 2009 , 16 Suppl A, 5A-14A	14

231	Evaluation of Different Asthma Phenotype Responses to Montelukast Versus Fluticasone Treatment. 2009 , 22, 63-68	5
230	Predictors of poor response during asthma therapy differ with definition of outcome. 2009 , 10, 1231-42	45
229	Medicamenteuze onderhoudsbehandeling. 2009 , 77, 243-249	1
228	Leukotriene-E4 in human urine: Comparison of on-line purification and liquid chromatography-tandem mass spectrometry to affinity purification followed by enzyme immunoassay. 2009 , 877, 3169-74	30
227	The pharmacogenetics of asthma treatment. 2009 , 9, 10-7	12
226	Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control with inhaled corticosteroid treatment. 2009 , 34, 693-701	28
225	Leukotriene pathway genetics and pharmacogenetics in allergy. 2009 , 64, 823-39	82
224	The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. 2009 , 103, 296-300	35
223	Repeatability of response to asthma medications. 2009 , 123, 385-90	17
222	Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. 2009 , 123, 411-6	89
221	The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. 2009 , 123, 1376-83.e7	89
220	Randomized trial of the effect of drug presentation on asthma outcomes: the American Lung Association Asthma Clinical Research Centers. 2009 , 124, 436-44, 444e1-8	82
219	Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. 2009 , 124, 942-8.e1-9	47
218	Asthma. 2009 , 360, 1002-14	355
217	Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma. 2009 , 10, 67	28
216	Montelukast in the treatment of asthma and beyond. 2009 , 5, 639-58	35
215	Pharmacogenetics of asthma. 2009 , 15, 57-62	60
214	5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. 2009 , 19, 244-7	55

213	Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough. 2010 , 59, 185-92	27
212	Recent advances in antileukotriene therapy. 2010 , 10, 370-6	28
211	Heterogeneity of response to asthma controller therapy: clinical implications. 2010 , 16, 13-8	11
210	The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos. 2010 , 40, 582-9	28
209	Leukotriene modifiers for asthma treatment. 2010 , 40, 1732-41	82
208	Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. 2010 , 16, 1299-304	436
207	Role of Leukotrienes and Leukotriene Modifiers in Asthma. 2010 , 3, 1792-1811	30
206	Immunomodulators for asthma. 2010 , 2, 228-34	12
205	Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma. 2010 , 26, 1295-305	10
204	What's new in asthma pathophysiology and immunopathology?. 2010 , 4, 605-29	25
203	Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists. 2010 , 184, 2219-25	25
202	GPR17 regulates immune pulmonary inflammation induced by house dust mites. 2010 , 185, 1846-54	34
201	A pharmacovigilance study on patients of bronchial asthma in a teaching hospital. 2010 , 2, 333-6	3
200	Lessons learned from variation in response to therapy in clinical trials. 2010 , 125, 285-92; quiz 293-4	38
199	The evolving role of intravenous leukotriene modifiers in acute asthma. 2010 , 125, 381-2	7
198	The role of pharmacogenomics in improving the management of asthma. 2010 , 125, 295-302; quiz 303-4	24
197	Asthma Genomics. 2010 , 590-602	
196	The Genetics of Allergic Disease and Asthma. 2010 , 22-39	

195	Vitamin D levels, lung function, and steroid response in adult asthma. 2010 , 181, 699-704	286
194	Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial. 2010 , 28, 585-95	9
193	Impact of asthma controller medications on medical and economic resource utilization in adult asthma patients. 2010 , 26, 2851-60	16
192	Asthma care in resource-poor settings. 2011 , 4, 68-72	12
191	[Montelukast in the treatment of mild to moderate persistent asthma]. 2011 , 28, 706-29	1
190	The pharmacogenetics and pharmacogenomics of asthma therapy. 2011 , 11, 383-92	48
189	Leukotriene antagonists as first-line or add-on asthma-controller therapy. 2011 , 364, 1695-707	192
188	Comparison of leukotriene receptor antagonists and anti-histamines as an add-on therapy in patients with asthma complicated by allergic rhinitis. 2011 , 58, 9-14	5
187	Can inhaled corticosteroids prevent asthma exacerbations?. 2011 , 17, 16-22	4
186	Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues. 2011 , 2, 35	14
185	Pharmacogenetics [Therapeutic Area] Respiratory. 154-174	
184	The increasing challenge of discovering asthma drugs. 2011 , 82, 586-99	38
183	Dexamethasone-induced FKBP51 expression in peripheral blood mononuclear cells could play a role in predicting the response of asthmatics to treatment with corticosteroids. 2011 , 31, 122-7	21
182	Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. 2011 , 11, 526-38	33
181	Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. 2011 , 51, 751-60	52
180	Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. 2011 , 183, 449-54	45
179	Asthma in sickle cell disease: implications for treatment. 2011 , 2011, 740235	6
178	Montelukast in asthma: a review of its efficacy and place in therapy. 2011 , 2, 47-58	34

177	A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. 2012 , 185, 612-9	362
176	Pharmacogenomic Testing in the Asthma Clinic: Will Inhaled Corticosteroids Lead the Way?. 2012 , 25, 44-47	1
175	Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. 2012 , 12, CD009611	5
174	Cysteinyl leukotriene receptors, old and new; implications for asthma. 2012 , 42, 1313-20	78
173	New approaches to personalized medicine for asthma: where are we?. 2012 , 129, 327-34	31
172	Genetic basis for personalized medicine in asthma. 2012 , 6, 223-36	31
171	Discovery and Development of Montelukast (Singulair®). 2012 , 154-195	6
170	Asthma: the paradox of heterogeneity. 2012 , 129, 1200-1	14
169	[Asthma exacerbations: pharmacological prevention]. 2012 , 29, 232-44	1
168	Treating according to asthma control: does it work in real life?. 2012 , 33, 505-17	8
167	Airway obstruction lability helps distinguish levels of disease activity in asthma. 2012 , 106, 500-7	5
166	Trials and tribulations in identifying new biologic treatments for asthma. 2012 , 33, 238-46	38
165	Evidence-Based Child Health Clinical Answer: Intervention. 2012 , 7, 1404-1408	0
164	Designing a series of decision-theoretic phase II trials in a small population. 2012 , 31, 4337-51	5
163	Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. 2012 , 7, 13	9
162	Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. 2012 , CD002314	78
161	The asthma disease activity score: a discriminating, responsive measure predicts future asthma attacks. 2012 , 130, 1071-1077.e10	15
160	Fruit juices as perpetrators of drug interactions: the role of organic anion-transporting polypeptides. 2012 , 92, 622-30	49

159	Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. 2012 , 4, 367-83	34
158	Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second. 2012 , 68, 1157-66	12
157	A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. 2012 , 42, 38-48	164
156	Comparison of inhaled corticosteroids and leukotriene receptor antagonists in adolescents and adults with mild to moderate asthma: a meta-analysis. 2013 , 7, 74-90	4
155	Pharmacogenetics and the development of personalized approaches for combination therapy in asthma. 2013 , 13, 443-52	9
154	A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation. 2013 , 13, 20	20
153	Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. 2013 , CD009611	38
152	Management of asthma during pregnancy. 2013 , 7, 87-100	20
151	Genetic mapping with multiple levels of phenotypic information reveals determinants of lymphocyte glucocorticoid sensitivity. 2013 , 93, 735-43	17
150	Antileukotriene agents for the treatment of lung disease. 2013 , 188, 538-44	47
149	Stratified approaches to the treatment of asthma. 2013 , 76, 277-91	31
148	Impact of botanical oils on polyunsaturated fatty acid metabolism and leukotriene generation in mild asthmatics. 2013 , 12, 141	27
147	Comparative effectiveness research - what is it and how does one do it?. 2013 , 14, 152-6	6
146	Personalised medicine and asthma diagnostics/management. 2013 , 13, 118-29	15
145	Bitter taste receptors on airway smooth muscle as targets for novel bronchodilators. 2013 , 17, 721-31	30
144	Effect of montelukast for treatment of asthma in cigarette smokers. 2013 , 131, 763-71	43
143	The misuse of asthma drugs. 2013 , 7, 307-20	2
142	Update on allergen immunotherapy for treatment of allergic diseases. 2013 , 60, 141-65	1

141	Role of interactions in pharmacogenetic studies: leukotrienes in asthma. 2013 , 14, 923-9	3
140	Asthma pharmacogenetics: responding to the call for a personalized approach. 2013 , 13, 399-409	7
139	EAACI position statement on asthma exacerbations and severe asthma. 2013 , 68, 1520-31	81
138	The effects of airway microbiome on corticosteroid responsiveness in asthma. 2013 , 188, 1193-201	244
137	Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. 2013 , 288, 10967-72	129
136	Inter-ethnic differences in lymphocyte sensitivity to glucocorticoids reflect variation in transcriptional response. 2013 , 13, 121-9	23
135	Respiratory guidelines--which real world?. 2014 , 11 Suppl 2, S85-91	20
134	Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. 2014 , 311, 2083-91	179
133	Right answers, wrong questions in clinical research. 2014 , 6, 221fs5	7
132	Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study. 2014 , 10, 21	10
131	Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. 2014 , 133, 664-9.e5	56
130	Genome-wide association study identifies ALLC polymorphisms correlated with FEV ₁ change by corticosteroid. 2014 , 436, 20-6	19
129	Asthma. 2014 , 617-651	2
128	In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. 2014 , 8, 1539-47	7
127	The bronchodilator response as a predictor of inhaled corticosteroid responsiveness in asthmatic children with normal baseline spirometry. 2014 , 49, 1162-9	12
126	Bitter taste receptor function in asthmatic and nonasthmatic human airway smooth muscle cells. 2014 , 50, 678-83	59
125	Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study. 2014 , 134, 908-915.e3	36
124	High-performance liquid chromatographic determination of montelukast sodium in human plasma: Application to bioequivalence study. 2014 , 26, 457-472	7

123	Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , 2015 , 163, 756-67	8	29
122	Association between TAAR6 polymorphisms and airway responsiveness to inhaled corticosteroids in asthmatic patients. 2015 , 25, 334-42		6
121	Comparison of Glucocorticoid (Budesonide) and Antileukotriene (Montelukast) Effect in Patients with Bronchial Asthma Determined with Body Plethysmography. 2015 , 23, 347-51		3
120	Tandem Benzophenone Amino Pyridines, Potent and Selective Inhibitors of Human Leukotriene C4 Synthase. 2015 , 355, 108-16		18
119	Defining phenotypes in rhinitis: a step toward personalized medicine. 2015 , 135, 151-2		9
118	Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. 2015 , 32, 37-44		71
117	Evolving Concepts of Asthma. 2015 , 192, 660-8		159
116	Pharmacotherapy of critical asthma syndrome: current and emerging therapies. 2015 , 48, 7-30		11
115	Pharmacogenomics in asthma therapy: where are we and where do we go?. 2015 , 55, 129-47		25
114	Asthma phenotypes: the intriguing selective intervention with Montelukast. 2016 , 2, 11		12
113	Pivotal efficacy trials of inhaled corticosteroids in asthma. 2016 , 117, 582-588		10
112	GLCCI1 Variation Is Associated with Asthma Susceptibility and Inhaled Corticosteroid Response in a Chinese Han Population. 2016 , 47, 118-25		21
111	Montelukast, current indications and prospective future applications. 2016 , 10, 943-56		8
110	Predictors of future exacerbation risk in patients with asthma. 2016 , 128, 687-92		9
109	Leukotriene Receptor Antagonists and Antiallergy Drugs. 2017 , 237, 153-169		18
108	A randomized placebo-controlled trial of traditional Chinese medicine as an add-on therapy to oral montelukast in the treatment of mild persistent asthma in children. 2016 , 29, 219-228		14
107	The Danish National Database for Asthma: establishing clinical quality indicators. 2016 , 3, 33903		1
106	Addressing corticosteroid insensitivity in adults with asthma. 2016 , 10, 137-56		10

105	Evaluation of switching low-dose inhaled corticosteroid to pranlukast for step-down therapy in well-controlled patients with mild persistent asthma. 2016 , 53, 207-12	8
104	The Genetics of Allergic Disease and Asthma. 2016 , 18-30.e4	
103	Asthma. 2017 , 151-204	5
102	Tiotropium for the treatment of asthma in adolescents. 2017 , 18, 305-312	6
101	Why evidence-based medicine failed in patient care and medicine-based evidence will succeed. 2017 , 84, 14-17	17
100	Pharmacogenomics of inhaled corticosteroids and leukotriene modifiers: a systematic review. 2017 , 47, 271-293	27
99	The effect of allergen-induced bronchoconstriction on concentration of 5-oxo-EETE in exhaled breath condensate of house dust mite-allergic patients. 2017 , 47, 1253-1262	10
98	Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. 2017 , 18, 931-943	22
97	Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast. 2017 , 3, 3	7
96	Patient stratification and the unmet need in asthma. 2017 , 169, 13-34	17
95	GLCCI1 rs37973: A potential genetic predictor of therapeutic response to inhaled corticosteroids in Chinese asthma patients. 2017 , 96, e9442	11
94	Asthma. 2017 , 231-244	
93	A simple prediction tool for inhaled corticosteroid response in asthmatic children. 2017 , 17, 176	8
92	Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids. 2018 , 134, 143-149	35
91	A Novel Orally Available Asthma Drug Candidate That Reduces Smooth Muscle Constriction and Inflammation by Targeting GABA Receptors in the Lung. 2018 , 15, 1766-1777	19
90	Leukotriene E induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor. 2018 , 142, 1080-1089	27
89	Montelukast Treatment of Acute Asthma Exacerbations in Children Aged 2 to 5 Years: A Randomized, Double-Blind, Placebo-Controlled Trial. 2018 , 34, 160-164	7
88	Treatment response heterogeneity in asthma: the role of genetic variation. 2018 , 12, 55-65	23

87	Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls. 2018 , 20, 1-7	2
86	Inhaled Corticosteroid Therapy for Asthma. 2018 , 1-35	
85	Effect of a Novel Photoelectrochemical Oxidation Air Purifier on Nasal and Ocular Allergy Symptoms. 2018 , 9, 2152656718781609	5
84	The Variants in the 3' Untranslated Region of the Matrix Metalloproteinase 9 Gene as Modulators of Treatment Outcome in Children with Asthma. 2018 , 196, 297-303	2
83	FeNO monitoring to adjust treatment in asthma: has it come of age?. 2018 , 73, 1095-1096	3
82	Differential long-term regulation of TAS2R14 by structurally distinct agonists. 2019 , 33, 12213-12225	6
81	A Comparison of Leukotriene Receptor Antagonists to Low-Dose Inhaled Corticosteroids in the Elderly with Mild Asthma. 2019 , 7, 2642-2652.e3	4
80	Current state and future prospect of the therapeutic strategy targeting cysteinyl leukotriene metabolism in asthma. 2019 , 57, 534-543	10
79	Upregulation of microRNA-16 alters the response to inhaled agonists in patients with asthma though modulating expression of ADRB2. 2019 , 19, 4027-4034	8
78	Asthma and Corticosteroid Responses in Childhood and Adult Asthma. 2019 , 40, 163-177	17
77	Inhaled Corticosteroid Therapy for Asthma. 2019 , 873-907	
76	Targeting lipid mediators in asthma: time for reappraisal. 2019 , 25, 121-127	9
75	Pharmacology of the Airways. 2019 , 151-164	
74	Genetic associations of the response to inhaled corticosteroids in asthma: a systematic review. 2019 , 9, 2	24
73	Cysteinyl maresins regulate the proinflammatory lung actions of cysteinyl leukotrienes. 2020 , 145, 335-344	22
72	Identification and Characterization of Novel Bronchodilator Agonists Acting at Human Airway Smooth Muscle Cell TAS2R5. 2020 , 3, 1069-1075	1
71	Integral Membrane Enzymes in Eicosanoid Metabolism: Structures, Mechanisms and Inhibitor Design. 2020 , 432, 4999-5022	4
70	Sarcoidosis exosomes stimulate monocytes to produce pro-inflammatory cytokines and CCL2. 2020 , 10, 15328	7

69	New perspectives in bronchial asthma: pathological, immunological alterations, biological targets, and pharmacotherapy. 2020 , 42, 521-544	4
68	G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action. 2020 , 72, 1-49	33
67	Con: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment. 2021 , 17, 210049	1
66	Eicosanoid receptors as therapeutic targets for asthma. 2021 , 135, 1945-1980	4
65	Structures and Agonist Binding Sites of Bitter Taste Receptor TAS2R5 Complexed with Gi Protein and Validated against Experiment. 2021 , 12, 9293-9300	2
64	LTA4H rs2660845 association with montelukast response in early and late-onset asthma. 2021 , 16, e0257396	1
63	Medical Management of Asthma. 2010 , 89-105	1
62	Leukotrienes in asthma. 2003 , 525, 1-5	16
61	Genetic regulation of leukotriene production and activity. 2002 , 137-166	2
60	Antileukotriene Therapy in Asthma. 2009 , 1619-1632	1
59	Approach to the Patient with Exercise-Induced Bronchoconstriction. 2014 , 938-950	1
58	Treating children with asthma. A review of drug therapies. 2001 , 174, 415-20	6
57	Leukotriene receptor antagonist therapy. 2000 , 76, 767-73	19
56	Montelukast added to inhaled beclomethasone in treatment of asthma. 2000 , 162, 331-2	2
55	Comparison of cellular and transcriptional responses to 1,25-dihydroxyvitamin d3 and glucocorticoids in peripheral blood mononuclear cells. 2013 , 8, e76643	7
54	Nocturnal Asthma: A Special Type of Asthma. 003-009	2
53	Managing asthma in the 21st century: role of pharmacogenetics. 2006 , 35, 660-2, 664-9	10
52	Effects of Glucocorticoid-Induced Transcript 1 Gene Deficiency on Glucocorticoid Activation in Asthmatic Mice. 2018 , 131, 2817-2826	8

51 Treatment of Asthma in Adults. **2001**, 201-231

50 Leukotrienes and Antileukotriene Therapy in Severe Asthma. **2001**, 153-165

49 Asthmabehandlung. **2002**, 23,

48 The step 3 dilemma for moderate persistent asthma. **2002**, 165, 1022-3; author reply 1023

47 Initial therapy in clinical asthma studies often does not equal therapy for mild, persistent asthma. **2002**, 165, 1022; author reply 1022

46 National Heart, Lung, and Blood Institute Guidelines: Treatment of Asthma. **2003**, 123-134

45 Inhaled Corticosteroids and Their Use in Asthma. **2003**, 135-150

44 Leukotriene Modifiers in the Treatment of Asthma. **2003**, 193-199

43 Therapy for Virus-Induced Asthma Exacerbations Current Status and Future Prospects. **2003**,

42 Pulmonary Diseases. **2004**, 375-414

41 Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision-Making. **2006**, 199-223

40 Antagonists of leukotriene receptors in treatment of patients with bronchial asthma. **2008**, 101-107

39 Pharmacogenomics of Asthma Therapies. **2009**, 1633-1642

38 Lipid Mediators of Hypersensitivity and Inflammation. **2009**, 203-221

1

37 Asthma Genomics. **2009**, 1084-1097

36 Sputum Tests and Exhaled NO in the Diagnosis and Monitoring of Asthma. **2009**, 81-100

35 Antileukotrienes in Asthma and Rhinitis. **2009**, 63-90

34 Choice of Supplementary Therapy in Elderly Asthmatic Patients Comparison Between a Leucotriene Receptor Antagonist (Zafirlukast) and an Inhaled Steroid (Fluticasone Propionate). **2009**, 55, 303-308

- 33 New Insight into the Pathogenesis and Management of Refractory Childhood Asthma. **2010**, 442-454
- 32 Pharmacology of the Airways. **2011**, 121-132
- 31 Asthma: Identifying and Treating High-Risk Patients. **2012**, 159-172
- 30 Association between WDR21A polymorphisms and airway responsiveness to inhaled corticosteroids in asthmatic patients. **2012**, 22, 327-35 4
- 29 Pharmacogenomics of Allergy and Asthma. **2013**, 529-557
- 28 Asthma. **2013**, 659-676
- 27 Heterogeneity of response to therapy. **2014**, 795, 117-22
- 26 Systems biology approaches in asthma pharmacogenomics study. **2014**, 2, 326 1
- 25 Management of Asthma in Adolescents and Adults. **2014**, 902-922
- 24 Antileukotriene Therapy in Asthma. **2014**, 1602-1615
- 23 Lipid Mediators of Hypersensitivity and Inflammation. **2014**, 139-161 0
- 22 Pharmacogenomics of Asthma Therapies. **2014**, 1460-1470 1
- 21 Inhaled corticosteroids or antileukotrienes for asthma?. *Annals of Internal Medicine*, **1999**, 131, 865 8
- 20 Efficacy and safety of montelukast in patients with asthma and allergic rhinitis in routine clinical practice: results of a prospective multicenter observational program. **2016**, 13, 44-53
- 19 Comparison of Effect of Leukotriene Biosynthesis Blockers and Inhibitors of Phosphodiesterase Enzyme in Patients with Bronchial Hyperreactivity. **2018**, 6, 777-781 0
- 18 Genetics of Hypersensitivity. **2009**, 227-238
- 17 Antileukotriene Agents in the Management of Asthma. **2007**, 361-366
- 16 LTA4H association with montelukast response in early and late-onset asthma.

15	How well is the clinical importance of study results reported? An assessment of randomized controlled trials. 2001 , 165, 1197-202	21
14	Low dose inhaled corticosteroids and the prevention of death from asthma. 2001 , 56 Suppl 2, ii74-8	2
13	New treatments for asthma: the role of leukotriene modifier agents. 1999 , 91, 26S-39S	1
12	Monitoring asthma control using claims data and patient-reported outcomes measures. 2008 , 33, 454-66	2
11	Bitter taste receptors in the wrong place: novel airway smooth muscle targets for treating asthma. 2014 , 125, 64-74; discussion 74-5	15
10	Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline. 2021 , 204, e97-e109	7
9	Outcome Measures in Childhood Asthma. 2002 , 109, 393-398	11
8	Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses. EAACI task force on eicosanoids consensus report in times of COVID-19.. 2022 ,	0
7	AN OBSERVATIONAL STUDY TO ASSESS THE ADVERSE DRUG REACTION OF ANTI-ASTHMATIC DRUGS AMONG ADULTS IN WESTERN RAJASTHAN. 106-109	
6	The Chemical Elucidation of Slow-Reacting Substance: Bronchospasm and Beyond. 2018 , 200, 1535-1537	0
5	Structures of Leukotriene Biosynthetic Enzymes and Development of New Therapeutics. 2023 , 63,	1
4	A bibliometric and scientific knowledge map study of the drug therapies for asthma-related study from 1982 to 2021. 13,	0
3	Very important pharmacogenes polymorphism landscape and potential clinical relevance in the Chinese Mongolian. 2023 , 850, 146960	0
2	Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis.	1
1	Chemical Activation of Piezo1 Alters Biomechanical Behaviors toward Relaxation of Cultured Airway Smooth Muscle Cells. 2023 , 46, 1-11	1